Last edition
News about "Pepinemab Development Venture (PDV)"
Vaccinex Secures USD 60 Million Financing for Phase IIb Alzheimer's Trial
Vaccinex Inc has entered into a USD 60 million revenue-sharing agreement with Pepinemab Development Venture (PDV), LP to finance an expanded Phase IIb clinical trial of its anti-SEMA4D antibody, pepinemab, for the treatment of Alzheimer’s disease.
Pepinemab Development Venture (PDV) | 24/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members